Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Patterns of care in oligometastatic disease: the clinicians' perspective

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Second primary cancer following primary oral squamous cell carcinoma: a population-based, retrospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Systematisk måling af fysisk funktion hos voksne patienter på tværs af diagnoser

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Feasibility of Monitoring Patients Who Have Cancer With a Smart T-shirt: Protocol for the OncoSmartShirt Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of acute exercise training on tumor outcomes in men with localized prostate cancer: A randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The proportion of patients with locally advanced, unresectable or metastatic urothelial carcinoma that do not receive systemic anticancer treatment and the reasons for lack of treatment are largely unknown. The aim of this study was to investigate the prevalence and overall survival of this patient group and reasons for omission of treatment.

MATERIAL AND METHODS: This retrospective, single-center cohort study from Rigshospitalet, Denmark included patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma during the study period from 1 January 2010 to 31 March 2016 who did not receive systemic anticancer treatment. Patients were identified through the Danish Pathology Register and the electronic medical records.

RESULTS: 100 patients were included, representing 34% of all patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma at Rigshospitalet during the study period. Lack of treatment was most often due to poor physical condition (59%), decreased renal function (15%), or patient preferences (14%). Median overall survival was 1.9 months (95% CI: 1.6-2.8 months).

CONCLUSION: One in three patients diagnosed with locally advanced, unresectable or metastatic urothelial carcinoma in the pre-immunotherapy era did not receive systemic anticancer treatment. Prompt identification of advanced disease and interventions to optimize these patients for treatment are essential. Our findings underscore the compelling need for novel, better tolerated treatment regimens in this frail patient group.

Original languageEnglish
JournalActa Oncologica
Volume61
Issue number9
Pages (from-to)1036-1042
Number of pages7
ISSN0284-186X
DOIs
Publication statusPublished - Sep 2022

    Research areas

  • Carcinoma, Transitional Cell/therapy, Cohort Studies, Humans, Retrospective Studies, Urinary Bladder Neoplasms/pathology, Urologic Neoplasms/therapy

ID: 84432124